Rivaroxaban reduces stent thrombosis risk, study says

04/19/2013 | MedPage Today (free registration)

Adding the anticoagulant rivaroxaban to dual antiplatelet therapy decreased the chances of death and stent thrombosis among patients being treated for acute coronary syndrome, according to a study in the Journal of the American College of Cardiology. The findings were based on an analysis of a 9,631-patient subgroup of the ATLAS ACS 2-TIMI 51 trial.

View Full Article in:

MedPage Today (free registration)

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director of Accreditation
Meridian Health Plan
Detroit, MI
Stop Loss Sales Executive, (Southern Region)
Indigo Insurance Services
Multiple Locations, SL_Multiple Locations
Chief Executive Officer
Center for Improving Value in Healthcare
Denver, CO
Quality Program Manager II, State Programs
Tufts Health Plan
Watertown, MA
Senior director risk adjustor and coding doc
Novant Health
Charlotte, NC